OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press15210.17650/1818-8346-2015-10-3-44-52HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯPomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literatureПомалидомид в терапии рецидивирующей и рефрактерной множественной миеломы: презентация клинического случая и обзор литературыSemochkinS. V.СёмочкинСергей Вячеславович
Russian Federation

1 Ostrovityanov St., Moscow, 117997

117997, Москва, ул. Островитянова, 1

s.semochkin@gmail.comN. I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России0810201510344520710201507102015https://oncohematology.abvpress.ru/ongm/article/view/152

Relapsed and refractory multiple myeloma (MM) is defined as progression during anticancer therapy, or within 60 days of therapy completion. Patients with double resistance to bortezomib and lenalidomide that is two key anti-myeloma drugs are considered to have a very poor prognosis, and new regimens are needed to improve this setting. Pomalidomide is an immunomodulatory drug third generation, studied in combination with low-dose dexamethasone (LDD) as salvage therapy for patients with double refractory. This article reviews the clinical pharmacology, therapeutic efficacy and safety, dosage and administration, peculiar properties of the practical application of pomalidomide. The article is illustrated by the description of a 59-year-old woman with relapsed and refractory MM, who received pomalidomide in combination with LDD. Medical history prior to treatment with pomalidomide was included 8 lines of therapy conducted over 6.5 years, with the formation of the double refractory to lenalidomide and bortezomib. In March 2012, treatment with pomalidomide (4 mg days 1–21 of a 28-day cycle) and LDD (160 mg / cycle) has been started as the ninth line. In total, up to March 2014 the patient received 30 cycles of therapy with pomalidomide. After the first 2 cycles documented partial response (52 % reduction of IgGk), the deepest response is received after 10 cycles (82 % reduction). The patient is alive at the time of this article. The duration of response to pomalidomide is 25 months and overall survival from the time of his appointment is more than 37 months. In addition, this review presents the results of base clinical trials testing pomalidomide and LDD. Problems of development of new treatment regimens based on pomalidomide for relapsed and refractory MM are also discussed.

multiple myelomarefractory and relapsed multiple myelomapomalidomidedexamethasoneimmunomodulatory drugsalvage therapycase reportмножественная миеломарецидивирующая и рефрактерная множественная миеломапомалидомиддексаметазониммуномодулирующие препараты«терапия спасения»клинический случай1. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М.И. Давыдова, Е.М. Аксель. М.: РОНЦ им. Н.Н. Блохина, 2014. 226 с. [Statistics of malignant tumors in Russia and the CIS in 2012. Edited by M.I.Davydov, E.M.Aksel. M: N.N.Blochin RORC, 2014; 226 p. (In Russ.)].Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М.И. Давыдова, Е.М. Аксель. М.: РОНЦ им. Н.Н. Блохина, 2014. 226 с. [Statistics of malignant tumors in Russia and the CIS in 2012. Edited by M.I.Davydov, E.M.Aksel. M: N.N.Blochin RORC, 2014; 226 p. (In Russ.)].2. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2015. 250 с. [Malignancies in Russia in 2013 (morbidity and mortality). Edited by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: Gertsen MROI, 2015; 250 p. (In Russ)].Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2015. 250 с. [Malignancies in Russia in 2013 (morbidity and mortality). Edited by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: Gertsen MROI, 2015; 250 p. (In Russ)].3. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5–29.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5–29.4. Менделеева Л.П., Вотякова О.М., Покровская О.М. и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология 2014;59(S3):2–24. [Mendeleeva L.P., Votyakova O.M., Pokrovskaya O.M. et al. National clinical guidelines for diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya = Hematology and Transfusiology 2014;59(S3):2–24 (In Russ.)].Менделеева Л.П., Вотякова О.М., Покровская О.М. и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология 2014;59(S3):2–24. [Mendeleeva L.P., Votyakova O.M., Pokrovskaya O.M. et al. National clinical guidelines for diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya = Hematology and Transfusiology 2014;59(S3):2–24 (In Russ.)].5. Lonial S. Relapsed Multiple Myeloma. ASH Education Book 2010:2010(1):303–9.Lonial S. Relapsed Multiple Myeloma. ASH Education Book 2010:2010(1):303–9.6. Kumar S.K., Lee J.H., Lahuerta J.J. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma orking group study. Leukemia 2012;26(1):149–57.Kumar S.K., Lee J.H., Lahuerta J.J. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma orking group study. Leukemia 2012;26(1):149–57.7. Sehgal K., Das R., Zhang L. et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015;125(26):4042–51.Sehgal K., Das R., Zhang L. et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015;125(26):4042–51.8. Семочкин С.В. Биологические основы применения иммуномодулирующих препаратов в лечении множественной миеломы. Онкогематология 2010;(1):21–31. [Semochkin S.V. Biological basis of immunomodulatory preparations using in treatment of multiple myeloma. Onkogematologiya = Oncohematology 2010;1:21–31 (In Russ.)].]Семочкин С.В. Биологические основы применения иммуномодулирующих препаратов в лечении множественной миеломы. Онкогематология 2010;(1):21–31. [Semochkin S.V. Biological basis of immunomodulatory preparations using in treatment of multiple myeloma. Onkogematologiya = Oncohematology 2010;1:21–31 (In Russ.)].]9. Lopez-Girona A., Mendy D., Ito T. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26(11):2326–35.Lopez-Girona A., Mendy D., Ito T. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26(11):2326–35.10. Heintel D., Rocci A., Ludwig H. et al. Highexpression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013;161(5): 695–700.Heintel D., Rocci A., Ludwig H. et al. Highexpression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013;161(5): 695–700.11. Lu G., Middleton R.E., Sun H. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014;343(6168):305–9.Lu G., Middleton R.E., Sun H. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014;343(6168):305–9.12. Gandhi A.K., Kang J., Havens C.G. et al. Immunomodulatory agents lenalidomide and pomalidomide costimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol 2014;164(6):811–21.Gandhi A.K., Kang J., Havens C.G. et al. Immunomodulatory agents lenalidomide and pomalidomide costimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol 2014;164(6):811–21.13. Krönke J., Udeshi N.D., Narla A. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014;343(6168):301–5.Krönke J., Udeshi N.D., Narla A. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014;343(6168):301–5.14. Huang X., Di Liberto M., Jayabalan D. et al. Prolonged early G(1) arrest by selective CDK4/Huang X., Di Liberto M., Jayabalan D. et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood 2012;120(5):1095–106.15. Corral L.G., Haslett P.A., Muller G.W. et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380–6.Corral L.G., Haslett P.A., Muller G.W. et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380–6.16. Haslett P.A., Corral L.G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187(11):1885–92.Haslett P.A., Corral L.G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187(11):1885–92.17. Davies F.E., Raje N., Hideshima T. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210–6.Davies F.E., Raje N., Hideshima T. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210–6.18. Galustian C., Meyer B., Labarthe M.C. et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58(7):1033–45.Galustian C., Meyer B., Labarthe M.C. et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58(7):1033–45.19. Hanaizi Z., Flores B., Hemmings R. et al. The European medicines agency review of pomalidomide in combination with lowdose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2015;20(3): 329–34.Hanaizi Z., Flores B., Hemmings R. et al. The European medicines agency review of pomalidomide in combination with lowdose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2015;20(3): 329–34.20. Kasserra C., Assaf M., Hoffmann M. et al. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol 2015;55(2):168–78.Kasserra C., Assaf M., Hoffmann M. et al. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol 2015;55(2):168–78.21. Schey S.A., Fields P., Bartlett J.B. et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22(16):3269–76.Schey S.A., Fields P., Bartlett J.B. et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22(16):3269–76.22. Streetly M.J., Gyertson K., Daniel Y. et al. Alternate day pomalidomide retains antimyeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141(1):41–51.Streetly M.J., Gyertson K., Daniel Y. et al. Alternate day pomalidomide retains antimyeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141(1):41–51.23. Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27(3):5008–14.Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27(3):5008–14.24. Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010;24(11): 1934–99.Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010;24(11): 1934–99.25. Lacy M.Q., Allred J.B., Gertz M.A. et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118(11):2970–5.Lacy M.Q., Allred J.B., Gertz M.A. et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118(11):2970–5.26. Leleu X., Attal M., Arnulf B. et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 2013;121(11):1968–75.Leleu X., Attal M., Arnulf B. et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 2013;121(11):1968–75.27. Miguel J.S., Weisel K., Moreau P. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol 2013;14:1055–66.Miguel J.S., Weisel K., Moreau P. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol 2013;14:1055–66.28. Dimopoulos M.A., Palumbo A., Corradini P. et al. The STRATUS (MM-010) trial: a singlearm, phase 3b study evaluating safety and efficacy of pomalidomide + low dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. 20th Congress of the European Hematology Association. Haematologica 2015;100:abstr P273.Dimopoulos M.A., Palumbo A., Corradini P. et al. The STRATUS (MM-010) trial: a singlearm, phase 3b study evaluating safety and efficacy of pomalidomide + low dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. 20th Congress of the European Hematology Association. Haematologica 2015;100:abstr P273.29. Ito T., Ando H., Suzuki T. et al. Identification of a primary target of thalidomide teratogenicity. Science 2010;327(5971):1345–50.Ito T., Ando H., Suzuki T. et al. Identification of a primary target of thalidomide teratogenicity. Science 2010;327(5971):1345–50.30. Palumbo A., Rajkumar S.V., Dimopoulos M.A. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22(2):414–23.Palumbo A., Rajkumar S.V., Dimopoulos M.A. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22(2):414–23.31. Kristinsson S.Y. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program 2010;2010(1):437–44.Kristinsson S.Y. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program 2010;2010(1):437–44.32. Torimoto Y., Shindo M., Ikuta K., Kohgo Y. Current therapeutic strategies for multiple myeloma. Int J Clin Oncol 2015;20(3):423–30.Torimoto Y., Shindo M., Ikuta K., Kohgo Y. Current therapeutic strategies for multiple myeloma. Int J Clin Oncol 2015;20(3):423–30.33. Bianchi G., Richardson P.G., Anderson K.C. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol 2014;32(20):2125–32.Bianchi G., Richardson P.G., Anderson K.C. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol 2014;32(20):2125–32.34. Richardson P.G., Bensmaine A., Doerr T. et al. MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM). 2015 ASCO Annual Meeting. J Clin Oncol 2015;33(suppl):abstr TPS8610.Richardson P.G., Bensmaine A., Doerr T. et al. MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM). 2015 ASCO Annual Meeting. J Clin Oncol 2015;33(suppl):abstr TPS8610.35. Lacy M.Q., LaPlant B.R., Laumann K.M. et al. Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). 2014 ASH Annual Meeting. Blood 2014;124(21):304.Lacy M.Q., LaPlant B.R., Laumann K.M. et al. Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). 2014 ASH Annual Meeting. Blood 2014;124(21):304.36. Rosenbaum C.A., Kukreti V.A., Zonder J. et al. Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with LenalidomideExposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium MultiCenter Study. 2014 ASH Annual Meeting. Blood 2014;124(21):2109.Rosenbaum C.A., Kukreti V.A., Zonder J. et al. Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with LenalidomideExposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium MultiCenter Study. 2014 ASH Annual Meeting. Blood 2014;124(21):2109.37. Baz R., Martin T.G., Alsina M. et al. Pomalidomide, Cyclophosphamide, and Dexamethasone is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study. 2014 ASH Annual Meeting. Blood 2014;124(21):303.Baz R., Martin T.G., Alsina M. et al. Pomalidomide, Cyclophosphamide, and Dexamethasone is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study. 2014 ASH Annual Meeting. Blood 2014;124(21):303.38. Mateos M.V., Moreau Ph., Comenzo R. et al. An open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma. 20th Congress of the European Hematology Association. Haematologica 2015;100:abstr 275.Mateos M.V., Moreau Ph., Comenzo R. et al. An open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma. 20th Congress of the European Hematology Association. Haematologica 2015;100:abstr 275.39. Berenson J.R., Stampleman L., Bessudo A. et al. Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM). 2015 ASCO Annual Meeting. J Clin Oncol 2015;33(suppl):abstr. 8591.Berenson J.R., Stampleman L., Bessudo A. et al. Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM). 2015 ASCO Annual Meeting. J Clin Oncol 2015;33(suppl):abstr. 8591.40. Moreau P., Touzeau C. Multiple myeloma: from front-line to relapsed therapies. Am Soc Clin Oncol Educ Book 2015;35:e504–11.Moreau P., Touzeau C. Multiple myeloma: from front-line to relapsed therapies. Am Soc Clin Oncol Educ Book 2015;35:e504–11.